“We are delighted to receive FDA approval of the DETOUR System,” said Matt Thompson, MD, President, and CEO of Endologix. “PTAB therapy represents a significant step forward for patients with complex PAD, they have long needed a more effective and less invasive treatment option for long lesions of the SFA. We are proud to be pioneering this novel approach and continuing to innovate on behalf of patients. We look forward to launching this new therapy in the U.S. through a targeted market release in the coming weeks.”

Together, the companies will launch the world’s first ‘virtual heart clinic in a box’, revolutionising cardiac care for millions of patients by making it easy for any hospital or GP to deliver high-quality, remote patient monitoring to their patients.

“Advanced process automation has enabled a new level of miniaturization for our MSX multistage series to support next-generation imaging solutions that require smaller optical packages,” said Andrew Dereka, Thermoelectrics Product Director at Laird Thermal Systems